Tag: GlobeNewswire

In its first run on a real quantum processor, Quantum X Labs’ Qatacomb scheme successfully recovered an encrypted image using a 156-qubit machine, while an adversary without the key gained no usable information in the demonstration, illustrating a privacy guarantee designed to hold regardless of an adversary’s computing power

TEL AVIV, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (NASDAQ: QXL) (“Quantum X Labs” or the “Company”), a quantum technology company developing quantum computing, quantum sensing, quantum error correction and quantum applications technologies, today reported the first demonstration of its Qatacomb quantum encryption scheme on commercial quantum hardware.

In a run on an IBM Quantum Heron r2 processor, programmed through IBM’s open-source Qiskit framework, the intended recipient reconstructed an encrypted image by reading through the machine’s own noise, while an adversary who did not hold the key gained no usable information about the message.

The Company believes the significance lies in the kind of guarantee the scheme is designed to provide. Most encryption in use today rests on mathematical problems that are hard to solve with current computers, and a sufficiently capable quantum computer is widely expected to be able to break much of it. Qatacomb is instead designed so that its privacy follows from the structure of quantum states themselves: it is intended to be information-theoretic, meaning its security is not designed to depend on any assumption about how much computing power an adversary can bring to bear, now or in the future.

The demonstration moves Qatacomb from theory to testing on a real device. The intended recipient, holding the key, recovered the correct content for better than nine of every ten image elements and reconstructed the full image without error – despite the processor’s real noise. The adversary’s best possible measurement, evaluated exactly, returned no usable advantage.

About Quantum X Labs Inc.

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

 For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the intended security and privacy characteristics of Qatacomb, including its intended information-theoretic security and its design not to depend on assumptions regarding an adversary’s computing power; the potential significance, capabilities, benefits and applications of Qatacomb and the Company’s quantum encryption technologies; and the Company’s continued development, testing and commercialization of Qatacomb and its other quantum technologies. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the content of third-party websites.

IBM, IBM Quantum, Heron and Qiskit are trademarks or registered trademarks of International Business Machines Corporation. Use of these names does not imply any affiliation with, or endorsement by, International Business Machines Corporation.

Investor Relations Contacts:

Michal Efraty
Investor Relations
michal@efraty.com 

In its first run on a real quantum processor, Quantum X Labs’ Qatacomb scheme successfully recovered an encrypted image using a 156-qubit machine, while an adversary without the key gained no usable information in the demonstration, illustrating a privacy guarantee designed to hold regardless of an adversary’s computing power

TEL AVIV, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (NASDAQ: QXL) (“Quantum X Labs” or the “Company”), a quantum technology company developing quantum computing, quantum sensing, quantum error correction and quantum applications technologies, today reported the first demonstration of its Qatacomb quantum encryption scheme on commercial quantum hardware.

In a run on an IBM Quantum Heron r2 processor, programmed through IBM’s open-source Qiskit framework, the intended recipient reconstructed an encrypted image by reading through the machine’s own noise, while an adversary who did not hold the key gained no usable information about the message.

The Company believes the significance lies in the kind of guarantee the scheme is designed to provide. Most encryption in use today rests on mathematical problems that are hard to solve with current computers, and a sufficiently capable quantum computer is widely expected to be able to break much of it. Qatacomb is instead designed so that its privacy follows from the structure of quantum states themselves: it is intended to be information-theoretic, meaning its security is not designed to depend on any assumption about how much computing power an adversary can bring to bear, now or in the future.

The demonstration moves Qatacomb from theory to testing on a real device. The intended recipient, holding the key, recovered the correct content for better than nine of every ten image elements and reconstructed the full image without error – despite the processor’s real noise. The adversary’s best possible measurement, evaluated exactly, returned no usable advantage.

About Quantum X Labs Inc.

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

 For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the intended security and privacy characteristics of Qatacomb, including its intended information-theoretic security and its design not to depend on assumptions regarding an adversary’s computing power; the potential significance, capabilities, benefits and applications of Qatacomb and the Company’s quantum encryption technologies; and the Company’s continued development, testing and commercialization of Qatacomb and its other quantum technologies. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on Form 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the content of third-party websites.

IBM, IBM Quantum, Heron and Qiskit are trademarks or registered trademarks of International Business Machines Corporation. Use of these names does not imply any affiliation with, or endorsement by, International Business Machines Corporation.

Investor Relations Contacts:

Michal Efraty
Investor Relations
michal@efraty.com 

AS Harju Elekter Group is making a change in the management of its Finnish subsidiary, Harju Elekter Oy. As of today, 2 November 2026, Rauno Stüff will assume the position of Managing Director, succeeding the current Managing Director, Jari Jylli.

Electrification, investments in energy infrastructure, and growing demand for power distribution solutions are creating favorable growth opportunities in the Finnish electricity infrastructure market. At the same time, Harju Elekter Oy’s performance to date and the development of its higher value-added, project-based business have not met the Group’s expectations. To better capitalize on the opportunities available in the market, Harju Elekter Group considers it necessary to strengthen the company’s sales and marketing activities, further develop customer relationships, and accelerate the implementation of strategic changes. The purpose of this management change is to provide a clearer focus for these initiatives, enhance Harju Elekter Oy’s competitiveness, and create the conditions for the company’s long-term profitable growth.

Rauno Stüff holds a master’s degree in international business administration from Concordia International University Estonia and has further developed his expertise through various international leadership and business management programmes. He has more than 25 years of experience in sales, marketing, business development, and corporate management. Throughout his career, he has held senior management positions at Procter & Gamble, Saku Õlletehas, Olympic Entertainment Group, Omniva, Brenstol (Thermory), and Apollo Kino. Most recently, he served as Chief Executive Officer and Commercial Director of Örum Group / Mercantile AS, where he was responsible for managing business operations in Estonia and Finland. Rauno Stüff owns 327 shares in Harju Elekter Group.

Harju Elekter expresses its gratitude to its outgoing Managing Director Jari Jylli for his contributions to the company and extends its best wishes for his future endeavors.

Harju Elekter is an international industrial group with extensive experience in providing future proof solutions for electrical power distribution. We engineer, manufacture, and install electrification solutions for utilities, industries, infrastructure, public and commercial buildings. The entities of Harju Elekter Group in Estonia, Finland, Sweden, and Lithuania employ around 845 people, and the Group’s revenue in nine months of 2026 was 118.2 million euros.

Tiit Atso
Chairman of the Management Board
Tel +372 674 7400

AS Harju Elekter Group is making a change in the management of its Finnish subsidiary, Harju Elekter Oy. As of today, 2 November 2026, Rauno Stüff will assume the position of Managing Director, succeeding the current Managing Director, Jari Jylli.

Electrification, investments in energy infrastructure, and growing demand for power distribution solutions are creating favorable growth opportunities in the Finnish electricity infrastructure market. At the same time, Harju Elekter Oy’s performance to date and the development of its higher value-added, project-based business have not met the Group’s expectations. To better capitalize on the opportunities available in the market, Harju Elekter Group considers it necessary to strengthen the company’s sales and marketing activities, further develop customer relationships, and accelerate the implementation of strategic changes. The purpose of this management change is to provide a clearer focus for these initiatives, enhance Harju Elekter Oy’s competitiveness, and create the conditions for the company’s long-term profitable growth.

Rauno Stüff holds a master’s degree in international business administration from Concordia International University Estonia and has further developed his expertise through various international leadership and business management programmes. He has more than 25 years of experience in sales, marketing, business development, and corporate management. Throughout his career, he has held senior management positions at Procter & Gamble, Saku Õlletehas, Olympic Entertainment Group, Omniva, Brenstol (Thermory), and Apollo Kino. Most recently, he served as Chief Executive Officer and Commercial Director of Örum Group / Mercantile AS, where he was responsible for managing business operations in Estonia and Finland. Rauno Stüff owns 327 shares in Harju Elekter Group.

Harju Elekter expresses its gratitude to its outgoing Managing Director Jari Jylli for his contributions to the company and extends its best wishes for his future endeavors.

Harju Elekter is an international industrial group with extensive experience in providing future proof solutions for electrical power distribution. We engineer, manufacture, and install electrification solutions for utilities, industries, infrastructure, public and commercial buildings. The entities of Harju Elekter Group in Estonia, Finland, Sweden, and Lithuania employ around 845 people, and the Group’s revenue in nine months of 2026 was 118.2 million euros.

Tiit Atso
Chairman of the Management Board
Tel +372 674 7400

Materials Include a Technical Summary of the Photo-Mag Antenna Authored by Wolf Kohn, PhD, Chief Scientist of Project LightShift, and a Companion Explainer Video Prepared for Investor Audiences

Norwalk, CT, Nov. 02, 2026 (GLOBE NEWSWIRE) — Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced the publication of a package of investor explanatory materials on its corporate website, intended to help shareholders, analysts, and prospective investors understand the quantum antenna technology layer at the core of the Company’s platform.

The materials are available in the Investors section of the Company’s website at www.quantum-cyber.ai and consist of:

1. a technical summary presentation titled “Photo-Mag Antenna, Technical Summary,” authored by Wolf Kohn, PhD, Chief Scientist of Project LightShift, Inc., the inventor of the quantum photonic array technology exclusively licensed to Quantum Cyber for defense drone applications; and
2. a companion explainer video that walks investors through the same technology in plain language, prepared specifically for a non-technical investor audience.

On June 15, 2026, Quantum Cyber announced the execution of a definitive, exclusive worldwide Intellectual Property License Agreement with Project LightShift, Inc. covering the patent-protected quantum photonic array technology for integration into unmanned aerial vehicles and drone platforms used in defense and national security applications. Since that announcement, the Company has received a steady volume of investor questions seeking a clearer, more accessible description of what the quantum antenna technology actually is, how it works, and why management believes it differentiates the Company’s System-of-Systems platform from conventional autonomous defense integrators.

The materials published today respond to those questions. They are explanatory in nature, intended to make a highly technical body of work accessible to the investment community without diluting its substance.

The technical summary presentation, prepared by Dr. Kohn under Project LightShift, walks through the architecture and operating principles of the Photo-Mag Antenna, including:

• the polymer multilayer array architecture, built from a 25 by 25 grid of nano “DOTs” per unit, designed for high manufacturing yield and sub-0.1-watt power consumption;
• the signal conversion chain, in which the antenna subsystem traps photon streams at multiple frequencies, converts them into a single-frequency, phase-coherent photon stream, and routes the result into storage and processing;
• the DOT-level control circuit, which uses probability densities to incorporate quantum-level uncertainty into a practical, manufacturable control law;
• the DOT-level thermal control approach, driven by ambient light and molecular laser diodes;
• UV-lithography-based manufacturing controls, including the Hamiltonian ACS film generator and near-field self-assembly device under development to produce the array at scale.

Taken together, the summary describes the physical, control, and manufacturing layers that make the Photo-Mag Antenna a candidate for secure, frequency-agile sensing and communications in contested and denied environments, which is the capability the Company has licensed for defense drone and counter-UAS use.

The companion video runs approximately five minutes and presents the same material in a plain-language format intended for investors who want to understand the technology at a conceptual level without working through the technical slides. The video and the technical summary are designed to be used together, and investors who want a fuller picture are encouraged to review both.

About Quantum Cyber
Quantum Cyber N.V. (Nasdaq: QUCY) is a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications. The Company holds an exclusive worldwide license to Project LightShift’s patent-protected quantum photonic array technology for defense drone and unmanned aerial vehicle applications and is advancing vertically integrated U.S.-based manufacturing at its facility in Bridgeport, Connecticut. Additional information is available at www.quantum-cyber.ai.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding the capabilities, development status, and intended applications of the Photo-Mag Antenna and the quantum photonic array technology licensed from Project LightShift, Inc., the Company’s System-of-Systems platform, the Company’s manufacturing plans, and the usefulness of the explanatory materials to investors. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are outside the Company’s control, that could cause actual results to differ materially from those expressed or implied. Factors that could cause such differences include, without limitation, technical and engineering risk, manufacturing risk, regulatory risk, competition, defense budget and procurement risk, and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
qucy@arxhq.com

Materials Include a Technical Summary of the Photo-Mag Antenna Authored by Wolf Kohn, PhD, Chief Scientist of Project LightShift, and a Companion Explainer Video Prepared for Investor Audiences

Norwalk, CT, Nov. 02, 2026 (GLOBE NEWSWIRE) — Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications, today announced the publication of a package of investor explanatory materials on its corporate website, intended to help shareholders, analysts, and prospective investors understand the quantum antenna technology layer at the core of the Company’s platform.

The materials are available in the Investors section of the Company’s website at www.quantum-cyber.ai and consist of:

1. a technical summary presentation titled “Photo-Mag Antenna, Technical Summary,” authored by Wolf Kohn, PhD, Chief Scientist of Project LightShift, Inc., the inventor of the quantum photonic array technology exclusively licensed to Quantum Cyber for defense drone applications; and
2. a companion explainer video that walks investors through the same technology in plain language, prepared specifically for a non-technical investor audience.

On June 15, 2026, Quantum Cyber announced the execution of a definitive, exclusive worldwide Intellectual Property License Agreement with Project LightShift, Inc. covering the patent-protected quantum photonic array technology for integration into unmanned aerial vehicles and drone platforms used in defense and national security applications. Since that announcement, the Company has received a steady volume of investor questions seeking a clearer, more accessible description of what the quantum antenna technology actually is, how it works, and why management believes it differentiates the Company’s System-of-Systems platform from conventional autonomous defense integrators.

The materials published today respond to those questions. They are explanatory in nature, intended to make a highly technical body of work accessible to the investment community without diluting its substance.

The technical summary presentation, prepared by Dr. Kohn under Project LightShift, walks through the architecture and operating principles of the Photo-Mag Antenna, including:

• the polymer multilayer array architecture, built from a 25 by 25 grid of nano “DOTs” per unit, designed for high manufacturing yield and sub-0.1-watt power consumption;
• the signal conversion chain, in which the antenna subsystem traps photon streams at multiple frequencies, converts them into a single-frequency, phase-coherent photon stream, and routes the result into storage and processing;
• the DOT-level control circuit, which uses probability densities to incorporate quantum-level uncertainty into a practical, manufacturable control law;
• the DOT-level thermal control approach, driven by ambient light and molecular laser diodes;
• UV-lithography-based manufacturing controls, including the Hamiltonian ACS film generator and near-field self-assembly device under development to produce the array at scale.

Taken together, the summary describes the physical, control, and manufacturing layers that make the Photo-Mag Antenna a candidate for secure, frequency-agile sensing and communications in contested and denied environments, which is the capability the Company has licensed for defense drone and counter-UAS use.

The companion video runs approximately five minutes and presents the same material in a plain-language format intended for investors who want to understand the technology at a conceptual level without working through the technical slides. The video and the technical summary are designed to be used together, and investors who want a fuller picture are encouraged to review both.

About Quantum Cyber
Quantum Cyber N.V. (Nasdaq: QUCY) is a Nasdaq-listed autonomous defense technology company assembling an AI-powered System-of-Systems platform for drone warfare, counter-UAS, and border security applications. The Company holds an exclusive worldwide license to Project LightShift’s patent-protected quantum photonic array technology for defense drone and unmanned aerial vehicle applications and is advancing vertically integrated U.S.-based manufacturing at its facility in Bridgeport, Connecticut. Additional information is available at www.quantum-cyber.ai.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding the capabilities, development status, and intended applications of the Photo-Mag Antenna and the quantum photonic array technology licensed from Project LightShift, Inc., the Company’s System-of-Systems platform, the Company’s manufacturing plans, and the usefulness of the explanatory materials to investors. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are outside the Company’s control, that could cause actual results to differ materially from those expressed or implied. Factors that could cause such differences include, without limitation, technical and engineering risk, manufacturing risk, regulatory risk, competition, defense budget and procurement risk, and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
qucy@arxhq.com

WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:

• Guggenheim 3rd Annual Healthcare Innovation Conference, fireside chat on Monday, November 9, 2026 at 8:30 a.m. ET in Boston.
• Stifel 2026 Healthcare Conference, fireside chat on Tuesday, November 10, 2026 at 1:20 p.m. ET in New York.
• Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 18, 2026 at 3:00 p.m. GMT/10:00 a.m. ET in London.

A live webcast of each presentation will be available in the Investors section of the Company’s website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:

• Guggenheim 3rd Annual Healthcare Innovation Conference, fireside chat on Monday, November 9, 2026 at 8:30 a.m. ET in Boston.
• Stifel 2026 Healthcare Conference, fireside chat on Tuesday, November 10, 2026 at 1:20 p.m. ET in New York.
• Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 18, 2026 at 3:00 p.m. GMT/10:00 a.m. ET in London.

A live webcast of each presentation will be available in the Investors section of the Company’s website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contacts

Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

— Conference Call and Webcast 8:30 a.m. ET November 5 —

PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, and provide a business update.

Conference Call & Webcast Details
Title:		Cognition Third Quarter 2026 Financial Results and Business Update
Date:		November 5, 2026
Time:		8:30 a.m. Eastern Time
Dial In:		Toll Free (US & Canada) 1-800-715-9871
US/International Toll:		1-646-307-1963
Conference ID:		9023814
Call me™:		https://registrations.events/easyconnect/9023814/recFvJxj663evg74H/
Webcast:		https://webcast.ir-events.com/bKXwO501v80

About Cognition Therapeutics 
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 

Contact Information:    Cognition Therapeutics, Inc.     info@cogrx.com

Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.

— Conference Call and Webcast 8:30 a.m. ET November 5 —

PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, and provide a business update.

Conference Call & Webcast Details
Title:		Cognition Third Quarter 2026 Financial Results and Business Update
Date:		November 5, 2026
Time:		8:30 a.m. Eastern Time
Dial In:		Toll Free (US & Canada) 1-800-715-9871
US/International Toll:		1-646-307-1963
Conference ID:		9023814
Call me™:		https://registrations.events/easyconnect/9023814/recFvJxj663evg74H/
Webcast:		https://webcast.ir-events.com/bKXwO501v80

About Cognition Therapeutics 
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 

Contact Information:    Cognition Therapeutics, Inc.     info@cogrx.com

Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com

This press release was published by a CLEAR® Verified individual.